| Age in years, Median (IQR) |
53(48–58) |
55(50–62) |
<0.001 |
52(47–57) |
55(50–62) |
<0.001 |
| Race |
|
|
<0.001 |
|
|
<0.001 |
| Caucasian (%) |
52.7 |
66.9 |
|
50.1 |
68.5 |
|
| African American (%) |
34 |
24.7 |
|
34.7 |
23.8 |
|
| Hispanic/Other (%) |
13.4 |
8.3 |
|
15.2 |
7.7 |
|
| Education with college degree (%) |
43.2 |
59.9 |
<0.001 |
42.6 |
61.1 |
<0.001 |
| Systolic BP, mmHg, Median (IQR) |
126(115–137) |
128(118–137) |
0.25 |
126(115–136) |
128(118–137) |
0.095 |
| LDL cholesterol, mg/dL, Median (IQR) |
104(81–128) |
112(91–137) |
<0.001 |
104(82–134) |
113(91–139) |
0.001 |
| HDL cholesterol, mg/dL, Median (IQR) |
46(38–55) |
52(43–61) |
<0.001 |
45(37–55) |
52(43–61) |
<0.001 |
| Taking BP medication (%) |
35.9 |
31.2 |
0.132 |
32.1 |
29.8 |
0.51 |
| Taking DM medication (%) |
8.7 |
7.6 |
0.55 |
7.8 |
6.5 |
0.5 |
| Taking cholesterol medication (%) |
34.9 |
30.1 |
0.12 |
33.7 |
31.6 |
0.54 |
| HIV clinical factors |
| Nadir CD4 (cells/μL), Median (IQR) |
248(144–336) |
— |
|
256(159–340) |
— |
|
| History of AIDS (%) |
14.2 |
— |
|
11 |
— |
|
| HIV RNA >50 copies/mL (%) |
17.9 |
— |
|
19.6 |
— |
|
| Substance use prevalence |
| Smoking status |
|
|
0.004 |
|
|
0.005 |
| Never (%) |
25.2 |
25.3 |
|
26.2 |
23.8 |
|
| Former (%) |
43.8 |
52.9 |
|
43.5 |
54.7 |
|
| Current (%) |
31.0 |
21.8 |
|
30.4 |
21.5 |
|
| Pack years of smoking, Median (IQR) |
5.6(0–22.9) |
1.8(0–21.5) |
0.018 |
5.6(0–21.4) |
3.1(0–21.9) |
0.19 |
| Any ETOH use 1–14 drinks/week (%) |
71.7 |
78.1 |
0.026 |
72.8 |
81 |
0.005 |
| Any ETOH use >14 drinks/week (%) |
21.4 |
26.8 |
0.049 |
23 |
27.3 |
0.17 |
| Any binge drinking/week (%) |
31.2 |
25.5 |
0.052 |
33.3 |
26.4 |
0.04 |
| Any stimulant use (%) |
44.8 |
31.0 |
<0.001 |
47.7 |
30.9 |
<0.001 |
| Cumulative years of stimulant use, Median (IQR) |
3.4(0.6–17.4) |
2.5(0.7–15.8) |
0.666 |
3.7(0.7–17.3) |
2.4(0.7–14.5) |
0.294 |
| Any marijuana use (%) |
58.8 |
54.9 |
0.23 |
59.8 |
55.3 |
0.21 |
| Cumulative years of marijuana use, Median (IQR) |
3.7(0.7–29.5) |
2.7(0.5–22.1) |
0.321 |
3.9(0.6–31.2) |
2.9(0.6–19.9) |
0.615 |
| Any inhaled nitrite use (%) |
50.1 |
40.6 |
0.003 |
52.1 |
40.8 |
0.002 |
| Cumulative years of inhaled nitrite use, Median (IQR) |
2.5(0.5–11.4) |
2(0.5–9.8) |
0.581 |
2.6(0.5–13.4) |
2.1(0.5–14.5) |
0.418 |
| Any EDD use (%) |
48.8 |
45.6 |
0.32 |
48.3 |
44.1 |
0.24 |
| Cumulative years of EDD use, Median (IQR) |
3.1(1.1–6.3) |
2.5(1–5.8) |
0.198 |
2.9(1.1–6) |
2.6(1–5) |
0.383 |
| Plaque/Stenosis Prevalence (%) |
| Prevalence of coronary artery calcium |
53.1 |
52.1 |
0.74 |
— |
— |
|
| Prevalence of any plaque |
— |
— |
|
77.7 |
74.6 |
0.32 |
| Prevalence of calcified plaque |
— |
— |
|
34.9 |
39.9 |
0.16 |
| Prevalence of non-calcified plaque |
— |
— |
|
63.1 |
52.7 |
0.004 |
| Prevalence of mixed plaque |
— |
— |
|
34.7 |
31.8 |
0.47 |
| Prevalence of coronary artery stenosis >50% |
— |
— |
|
16.8 |
14.5 |
0.39 |
